



Comparing the Effects of Treatment Before or After Surgery in Patients with Early-Stage Non-Small Cell Lung Cancer

What is the PROSPECT-Lung Trial?

The **PROSPECT-Lung Trial** is a clinical study for patients with early-stage non-small cell lung cancer (NSCLC). This study asks if we can lower the chance of your lung cancer coming back or spreading by either receiving therapy before and after surgery, or receiving therapy only after surgery.

Why is this trial important?

This research is important because it should help us answer the question of whether giving treatment both before and after surgery (perioperative treatment) or just after surgery (adjuvant treatment) leads to better outcomes in patients with operable stage II-III NSCLC. The goal is to find the most effective treatment strategy to improve survival, reduce recurrence, and enhance overall patient outcomes.

Who can join this trial?

You may be eligible to participate in this trial if you:

- Have been diagnosed with early-stage NSCLC.
- Have NSCLC that your doctor thinks can be treated with surgery.
- Are at least 18 years old.

Other criteria also determine eligibility. Your doctor or healthcare provider will discuss whether you can participate after reviewing your medical history and current health.

What does this trial involve?

You will be randomly assigned to one of two groups:

- **Group 1:** You will have **surgery** for your cancer and then will receive **chemotherapy** plus **immunotherapy**.
- **Group 2:** You will receive **chemotherapy + immunotherapy** followed by **surgery** followed by **immunotherapy**.

You will undergo regular clinic visits for:

- **Chemotherapy** and **immunotherapy** (or **immunotherapy** alone).
- **Blood tests, scans** (like CT scans), and physical exams to monitor your progress.
- **Follow-up visits** for several years to track your health and check for cancer recurrence.

How long will the trial last?

You will receive the assigned treatment for a certain number of cycles, typically lasting a few months to one year. After completing treatment, you will continue follow-up visits for several years, as part of the standard of care, to monitor your health and check for any signs of cancer recurrence. The total duration of your participation could extend up to 10 years or more, depending on the follow-up schedule.

Are there any costs? Will I get paid?

You will not be paid for joining the study. Check with your health care provider and insurance provider to find out what costs will and won't be covered in this trial.

Who is conducting this trial?

This trial is being conducted by the Alliance for Clinical Trials in Oncology and the SWOG Cancer Research Network. Alliance and SWOG both are part of a national research network funded by the National Cancer Institute (NCI) through the Clinical Trials Innovation Unit (CTIU).

Where can I get more information?

- **Talk** to your healthcare provider.
- **Contact** the NCI Cancer Information Service toll-free at 1-800-422-6237
- **Go to** ClinicalTrials.gov and search the national clinical trial number: NCT06632327
- **Visit** the Alliance website at [AllianceNCTN.org] or SWOG website at [SWOG.org].

Thank you for considering participating on the PROSPECT-Lung trial!
Your involvement helps to advance research and could potentially benefit future patients with lung cancer.